|Description||SST0116CL1 is a second-generation small molecule inhibitor of Hsp90, which leads to decreased expression of Hsp90 client proteins and reduced tumor cell proliferation and tumor growth.|
|Brife Description||SST0116CL1 is a second-generation small molecule inhibitor of Hsp90, which leads to decreased expression of Hsp90 client proteins and reduced tumor cell proliferation and tumor growth.|
|Storage||3 years -20oC powder, 6 months-80oC in solvent.|
3-Methyltoxoflavin is a novel Hsp90 inhibitor, which decreases the Hsp90-dependent client protein HER2 and induces cell death.
Luminespib, also known as AUY-922 (or NVP-AUY922), is a derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with po...
CPUY201112 is an N-terminal Hsp90 inhibitor, which leads to decreased expression of Hsp90 client proteins and may result in increased tumor cell apoptosis.
G-TPP is a mitochondria-targeted Hsp90 inhibitor that increases cell death in HeLa and MCF7 cells, consistently inhibits cell death induced by oxidative stress ...
SH-1242 is an analog of deguelin that binds the C-terminus of Hsp90 and inhibits its function, resulting in decreased tumor cell growth.
BIIB021 is An orally active, purine-scaffold, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. BIIB021 that is ...
WK88-1 inhibits Hsp90, resulting in decreased expression of Hsp90 client proteins and potentially leading to decreased tumor cell growth.
Alvespimycin (17-DMAG; KOS-1022; NSC 707545) is a potent, H2O-soluble Hsp90 inhibitor with IC50 of 62 nM.17-DMAG displays ~2 times potency against human Hsp90 t...